Is ticagrelor (Brilinta) safe and appropriate for use in patients with chronic kidney disease, and does it require any dose adjustment?

Ticagrelor in Chronic Kidney Disease

Ticagrelor is safe and appropriate for use in patients with chronic kidney disease without dose adjustment, including those with severe CKD (GFR <30 mL/min) and end-stage renal disease on hemodialysis. 1

Dosing and Pharmacokinetics in CKD

No dose adjustment is required for any degree of renal impairment. The FDA label explicitly states that ticagrelor requires no dosage modification in patients with renal impairment, including those with end-stage renal disease on dialysis 1.

Key Pharmacokinetic Data:

• In severe renal impairment (CrCl <30 mL/min), ticagrelor exposure (AUC and Cmax) was only 20% lower, while the active metabolite was 17% higher compared to normal renal function 2
• In hemodialysis patients, ticagrelor AUC and Cmax were 38% and 51% higher, respectively, but platelet inhibition remained similar to patients with normal renal function 1, 3
• Ticagrelor is not dialyzable—timing of hemodialysis (before or after dose) has minimal impact on drug levels or antiplatelet effects 1, 3
• The primary route of elimination is hepatic metabolism (58% fecal, 26% urinary), with <1% of unchanged drug excreted in urine 1

Clinical Efficacy in CKD

Ticagrelor demonstrates superior or equivalent efficacy compared to clopidogrel in patients with CKD and acute coronary syndromes. The evidence is particularly strong from guideline-endorsed data:

Guideline Evidence:

The 2014 AHA/ACC guidelines highlight a prespecified PLATO analysis showing that in patients with estimated GFR <60 mL/min (21% of PLATO participants), ticagrelor significantly reduced the primary cardiovascular endpoint by 23% (17.3% vs 22.0%; HR 0.77,95% CI 0.65-0.90) compared to clopidogrel, with a 4% absolute reduction in all-cause mortality 4. Critically, this benefit occurred without differences in major bleeding, fatal bleeding, or non-CABG-related major bleeding 4.

Recent Real-World Data:

• In severe CKD (GFR <30 mL/min) not on dialysis, ticagrelor/prasugrel reduced net adverse clinical events (NACE) compared to clopidogrel (25.0% vs 39.9%, p=0.036), driven by lower cardiovascular mortality and myocardial infarction, with no increase in major bleeding 5
• In STEMI patients with GFR <30 mL/min, ticagrelor/prasugrel showed lower 1-year mortality (11% vs 33%, p=0.04) without increased bleeding 6
• Meta-analyses confirm ticagrelor reduces MACE (RR 0.89,95% CI 0.80-0.99) and stroke (RR 0.66,95% CI 0.45-0.96) in CKD patients 7

Bleeding Risk Considerations

The bleeding profile of ticagrelor in CKD requires nuanced interpretation:

• TIMI major and minor bleeding: No significant difference between ticagrelor and clopidogrel in CKD patients 8
• BARC bleeding types 1-2 and 3-5: Significantly higher with ticagrelor (RR 1.95 and 1.70, respectively) 8
• However, no increase in fatal bleeding or intracranial hemorrhage in the PLATO CKD subgroup 4

The discrepancy between bleeding definitions suggests ticagrelor causes more minor/moderate bleeding but not life-threatening hemorrhage in CKD patients.

Practical Implementation

Standard Dosing:

• Loading dose: 180 mg orally
• Maintenance dose: 90 mg twice daily
• No adjustment needed regardless of CKD stage or dialysis status 9, 1

Key Monitoring Points:

• Maintain aspirin at 81 mg daily (higher aspirin doses reduce ticagrelor efficacy) 9
• Discontinue 5 days before surgery (vs. 7 days for prasugrel) 9, 10
• Consider gastroprotection with PPI in patients at high GI bleeding risk 11

When to Prefer Ticagrelor Over Clopidogrel in CKD:

1. Moderate-to-high risk ACS (elevated troponins, TIMI score ≥2) 4
2. Multivessel disease, diabetes, or prior MI (subgroups with greater benefit)
3. Patients with CYP2C19 loss-of-function alleles (clopidogrel hyporesponsiveness is common in CKD) 4

When to Consider Clopidogrel Instead:

1. History of intracranial hemorrhage (ticagrelor increases fatal ICH risk) 9, 12
2. Active major bleeding that has not resolved
3. Severe bleeding diathesis or very high bleeding risk scores
4. Patient intolerance to ticagrelor (dyspnea occurs in ~14% of patients)

Common Pitfalls to Avoid

1. Do not reduce ticagrelor dose in CKD—the standard 90 mg twice daily is appropriate even in severe renal impairment
2. Do not avoid ticagrelor solely due to dialysis—it is safe and effective in ESRD on hemodialysis
3. Do not use aspirin >100 mg daily with ticagrelor—this reduces efficacy 9
4. Do not assume all bleeding is equal—ticagrelor increases minor bleeding but not fatal hemorrhage in CKD

Contraindications Specific to CKD Context

• Absolute: History of intracranial hemorrhage 9, 12
• Relative: Active pathological bleeding, severe hepatic impairment (not renal) 1

The weight of guideline evidence and recent real-world data supports ticagrelor as safe and effective in CKD, including advanced stages, with standard dosing and no adjustment required.